[go: up one dir, main page]

UA104909C2 - Висококонцентрована фармацевтична композиція, що містить антитіло до cd20 - Google Patents

Висококонцентрована фармацевтична композиція, що містить антитіло до cd20

Info

Publication number
UA104909C2
UA104909C2 UAA201204338A UAA201204338A UA104909C2 UA 104909 C2 UA104909 C2 UA 104909C2 UA A201204338 A UAA201204338 A UA A201204338A UA A201204338 A UAA201204338 A UA A201204338A UA 104909 C2 UA104909 C2 UA 104909C2
Authority
UA
Ukraine
Prior art keywords
antibody
highly concentrated
formulations
pharmaceutical formulation
formulation
Prior art date
Application number
UAA201204338A
Other languages
English (en)
Russian (ru)
Inventor
Міхаель Адлер
Ганнс-Крістіан Малер
Олівер Боріс Штаух
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43732866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104909(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA104909C2 publication Critical patent/UA104909C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід належить до висококонцентрованої стабільної фармацевтичної композиції антитіла до CD20, що має фармацевтичну активність, такого, наприклад, як ритуксимаб, окрелізумаб або HuMab<CD20>, або суміші зазначених молекул антитіл, призначеної для підшкірної ін'єкції. Зокрема, описана композиція, яка містить в ефективній кількості антитіло до CD20, принаймні один фермент гуалуронідазу, у вигляді об'єднаної композиції або у вигляді форми, яку застосовують для спільного введення. Зазначені композиції містять також принаймні один забуферовуючий агент, такий, наприклад, як гістидиновий буфер, стабілізатор або суміш двох або більшої кількості стабілізаторів (наприклад, сахарид, такий, наприклад, як дигідрат α,α-трегалози або сахароза, і необов'язково метіонін як другий стабілізатор), неіоногенну поверхнево-активну речовину та принаймні один фермент гуалуронідазу в ефективній кількості. Описані також спосіб застосування композиції.
UAA201204338A 2009-09-11 2010-09-10 Висококонцентрована фармацевтична композиція, що містить антитіло до cd20 UA104909C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170110 2009-09-11
PCT/EP2010/063271 WO2011029892A2 (en) 2009-09-11 2010-09-10 Highly concentrated pharmaceutical formulations

Publications (1)

Publication Number Publication Date
UA104909C2 true UA104909C2 (uk) 2014-03-25

Family

ID=43732866

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204338A UA104909C2 (uk) 2009-09-11 2010-09-10 Висококонцентрована фармацевтична композиція, що містить антитіло до cd20

Country Status (41)

Country Link
US (6) US20110076273A1 (uk)
EP (5) EP4218715A1 (uk)
JP (4) JP5674788B2 (uk)
KR (3) KR20120051094A (uk)
CN (2) CN102686216B (uk)
AR (1) AR078161A1 (uk)
AU (1) AU2010294186B2 (uk)
BR (1) BR112012005017B8 (uk)
CA (1) CA2771571C (uk)
CL (1) CL2012000620A1 (uk)
CO (1) CO6440527A2 (uk)
CR (1) CR20120090A (uk)
CY (1) CY1117941T1 (uk)
DK (2) DK3061445T3 (uk)
DO (2) DOP2012000064A (uk)
EA (2) EA201792552A1 (uk)
EC (1) ECSP12011722A (uk)
ES (2) ES2953478T3 (uk)
FI (1) FI3061445T3 (uk)
GT (1) GT201200069A (uk)
HR (2) HRP20231019T1 (uk)
HU (2) HUE029078T2 (uk)
IL (2) IL218165A (uk)
LT (1) LT3061445T (uk)
MA (1) MA33592B1 (uk)
MX (3) MX2012002861A (uk)
MY (2) MY197773A (uk)
NZ (2) NZ621448A (uk)
PE (2) PE20121178A1 (uk)
PH (1) PH12016501002B1 (uk)
PL (2) PL3061445T3 (uk)
PT (1) PT3061445T (uk)
RS (1) RS54769B1 (uk)
SG (1) SG179030A1 (uk)
SI (2) SI2475353T1 (uk)
SM (2) SMT202300282T1 (uk)
TN (1) TN2012000101A1 (uk)
TW (2) TWI515020B (uk)
UA (1) UA104909C2 (uk)
WO (1) WO2011029892A2 (uk)
ZA (1) ZA201201605B (uk)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
MX2013012596A (es) 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130058976A1 (en) * 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Allergen-specific induced tolerogenic dendritic cells for allergy therapy
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
MX389346B (es) 2012-05-18 2025-03-20 Genentech Inc Formulaciones de anticuerpos monoclonales de alta concentración.
WO2014052717A2 (en) * 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Cd20-and egfr-binding proteins enhanced stability
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
KR20150106887A (ko) * 2012-12-12 2015-09-22 테바 파마슈티컬 인더스트리즈 리미티드 인간 성장 호르몬과 알부민의 융합, 이의 제형 및 용도
CA2896793A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HK1219413A1 (zh) * 2013-03-12 2017-04-07 Teva Pharmaceutical Industries Ltd. 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
CN110538322A (zh) * 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
BR112015027279A8 (pt) 2013-05-03 2018-01-30 Selecta Biosciences Inc métodos e composições para acentuar células t reguladoras cd4+
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
SG11201604710XA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015191969A1 (en) * 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Treating lymphomas
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
AU2015289619C1 (en) * 2014-07-16 2021-01-07 New York University Use of hyaluronidase for treatment of muscle stiffness
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
EP3193932B1 (en) * 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
CN104761645A (zh) * 2015-04-30 2015-07-08 山东禹王制药有限公司 α干扰素融合蛋白制剂及应用
DE102015107307B3 (de) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optisches Verfahren zur Gehaltsbestimmung von Hyaluronsäure
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
LT3124976T (lt) * 2015-07-28 2018-12-27 F. Hoffmann-La Roche Ag Patobulintas bakterinio endotoksino testas, skirtas endotoksinų aptikimui
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3388089B1 (en) * 2015-12-10 2022-05-18 Menicon Co., Ltd. Peptide composition
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
SG11201811661TA (en) 2016-07-29 2019-01-30 Oncternal Therapeutics Inc Uses of indolinone compounds
CN109843920B (zh) * 2016-08-29 2023-01-13 迪赞纳生命科学公开有限公司 抗cd3抗体制剂
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
MA46761A (fr) * 2016-11-10 2019-09-18 Translate Bio Inc Administration sous-cutanée d'arn messager
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
AU2018308930A1 (en) * 2017-07-28 2020-02-06 F. Hoffmann-La Roche Ag Bispecific antibody formulation
CN107596349A (zh) * 2017-10-26 2018-01-19 刘冬连 一种稳定的红细胞生成素制剂配方
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN107898756B (zh) * 2017-12-22 2020-11-20 东曜药业有限公司 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
EP3636752A4 (en) 2018-07-25 2021-04-28 Alteogen, Inc. NEW HYALURONIC ACID HYDROLYZING ENZYMUTANTS AND THE PHARMACEUTICAL COMPOSITION CONTAINING THIS
KR20210062027A (ko) * 2018-09-13 2021-05-28 에프. 호프만-라 로슈 아게 Csf-1r 항체 제제
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
CN111202845A (zh) * 2018-11-22 2020-05-29 上海医药集团股份有限公司 包含抗cd20抗体的药物配制剂及其制备方法和应用
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN114555117A (zh) * 2019-10-12 2022-05-27 百奥泰生物制药股份有限公司 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
WO2021094508A1 (en) * 2019-11-15 2021-05-20 F. Hoffmann-La Roche Ag Prevention of visible particle formation in aqueous protein solutions
CN114787191A (zh) * 2019-12-09 2022-07-22 基因泰克公司 抗pd-l1抗体制剂
CU20190104A7 (es) 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
JP7622088B2 (ja) 2020-08-07 2025-01-27 アルテオジェン・インコーポレイテッド 組換えヒアルロニダーゼの生産方法
AU2021330845A1 (en) * 2020-08-24 2023-01-19 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
MX2023007734A (es) 2020-12-28 2023-08-21 Bristol Myers Squibb Co Composiciones de anticuerpos y metodos de uso de las mismas.
KR20230129462A (ko) * 2020-12-30 2023-09-08 상하이 바오 파마슈티컬스 컴퍼니 리미티드 재조합 인간 히알루로니다제 제제 및 이의 응용
US20240197783A1 (en) 2021-04-21 2024-06-20 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN113855798A (zh) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 抗cd20的抗体制剂
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
IL316049A (en) * 2022-04-13 2024-11-01 Genentech Inc Musuntuzumab pharmaceutical preparations and methods of use
JP2025513510A (ja) * 2022-04-20 2025-04-24 アルトス バイオロジックス インク． オクレリズマブを含む薬学的組成物とその用途
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
MA70850A1 (fr) * 2022-07-26 2025-10-31 Joint Stock Company "Biocad" Composition pharmaceutique d'anticorps anti-cd20 et son utilisation
TW202517294A (zh) * 2023-07-11 2025-05-01 美商建南德克公司 用於治療多發性硬化症之組成物及方法
WO2025037336A1 (en) * 2023-08-12 2025-02-20 Dr. Reddy's Laboratories Limited Pharmaceutical formulations of anti-cd 20 antibody and methods of preparing the same
CN120514848B (zh) * 2025-07-28 2025-10-28 上海翰森生物医药科技有限公司 一种cd19抗体药物制剂

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
DE69233153T2 (de) 1991-03-06 2004-05-27 Merck Patent Gmbh Humanisierte monoklonale antikörper
JPH04346934A (ja) * 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DK1900751T3 (da) * 1996-11-27 2010-04-19 Genentech Inc Affinitetsoprensning af et polypeptid på Protein A-matrix
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
EP1946775A3 (en) 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
DK1131096T3 (da) * 1998-11-09 2010-05-17 Biogen Idec Inc Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
CA2350058C (en) 1998-11-09 2015-10-13 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
PL204629B1 (pl) 1999-06-25 2010-01-29 Genentech Inc Zastosowanie przeciwciała do wytwarzania leku do leczenia raka sutka, zastosowanie przeciwciała do leczenia raka jajnika, zastosowanie przeciwciała do wytwarzania leku do leczenia raka płuc i zastosowanie przeciwciała do leczenia raka okrężnicy, raka odbytnicy i raka jelita grubego i odbytu
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
IL149500A0 (en) * 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
SK12232002A3 (sk) 2000-02-25 2003-03-04 The Government Of The United States, As Represented By The Anti-ERGFRvIII scFv so zlepšenou cytotoxicitou a výťažkom, imunotoxíny a spôsoby ich použitia
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
JP2003533987A (ja) 2000-05-19 2003-11-18 イス ケミカル カンパニー リミテッド 表皮成長因子収容体に対するヒト化抗体
JP2004512262A (ja) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
HU231090B1 (hu) 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002034790A1 (en) * 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
ES2364816T3 (es) 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
CN100497389C (zh) 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
DE10153197A1 (de) 2001-10-27 2003-05-08 Merck Patent Gmbh Pigment mit Metallglanz
PL213311B1 (pl) 2002-02-14 2013-02-28 Chugai Pharmaceutical Co Ltd Preparat roztworu zawierajacego przeciwcialo
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
DK2289936T3 (en) * 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
WO2004060053A2 (en) * 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
NZ582315A (en) 2003-01-22 2011-01-28 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EA009383B1 (ru) 2003-03-05 2007-12-28 Хэлозим, Инк. РАСТВОРИМЫЙ ГЛИКОПРОТЕИН ГИАЛУРОНИДАЗЫ (sHASEGP), СПОСОБ ЕГО ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ЕГО СОДЕРЖАЩАЯ
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
RU2358762C9 (ru) 2003-04-09 2016-10-10 Джинентех, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2272868B1 (en) * 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
RU2370775C2 (ru) * 2003-07-29 2009-10-20 Дженентек, Инк. Анализ нейтрализующих антител и его применение
JP2007503435A (ja) 2003-08-26 2007-02-22 ベクトン・ディキンソン・アンド・カンパニー 治療薬の皮内送達法
BRPI0412629A (pt) * 2003-08-29 2006-09-26 Genentech Inc método de tratamento de disfunção ocular em mamìferos
DK2380910T3 (en) * 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
US20050191297A1 (en) * 2003-12-19 2005-09-01 Genentech, Inc. Detection of CD20 in transplant rejection
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
AU2005241431A1 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
RU2006140377A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Способ усиления уничтожения в-клеток
WO2005115453A2 (en) * 2004-04-16 2005-12-08 Genentech, Inc. Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
EP1773393A2 (en) 2004-05-05 2007-04-18 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
WO2005114218A2 (en) 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CN101027100A (zh) * 2004-07-22 2007-08-29 健泰科生物技术公司 治疗干燥综合征的方法
JP2008510466A (ja) * 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
BRPI0515604A (pt) * 2004-09-08 2008-07-29 Genentech Inc método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
US20090317384A1 (en) 2004-09-08 2009-12-24 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
KR20070100228A (ko) * 2004-10-05 2007-10-10 제넨테크, 인크. 혈관염의 치료 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PE20061075A1 (es) * 2004-12-17 2006-11-15 Genentech Inc Anticuerpos anti-vegf como agentes antiangiogenicos para tratar enfermedades autoinmunes en pacientes en quienes fallo una terapia anterior
EP1833970A2 (en) * 2004-12-22 2007-09-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
RU2007130688A (ru) * 2005-01-13 2009-02-20 Дженентек, Инк. (Us) Способ лечения
CN101111264A (zh) 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
US20060240007A1 (en) * 2005-04-22 2006-10-26 Genentech, Inc. Method for treating dementia or Alzheimer's disease
KR20080025066A (ko) * 2005-05-18 2008-03-19 바이오겐 아이덱 인크. 섬유성 상태의 치료 방법
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
CN103146708A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
AR055137A1 (es) 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
AU2006318539B2 (en) * 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
CA2634131C (en) 2005-12-21 2014-02-11 Wyeth Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
AU2007229554A1 (en) 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
JP5298021B2 (ja) 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
SI4365189T1 (sl) * 2007-07-09 2025-06-30 F. Hoffmann-La Roche Ag Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
US20110243931A1 (en) * 2007-09-02 2011-10-06 Thomas Friess Combination therapy with type i and type ii anti-cd20 antibodies
US20090214561A1 (en) * 2007-09-24 2009-08-27 David Robert Close Treatment method
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
HRP20150282T4 (hr) * 2007-10-30 2018-08-10 Genentech, Inc. Purifikacija protutijela pomoću kromatografije kationskom izmjenom
CN101945667A (zh) * 2007-12-21 2011-01-12 健泰科生物技术公司 利妥昔单抗不应性类风湿性关节炎患者的疗法
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
BRPI0909227B8 (pt) 2008-03-25 2021-05-25 Roche Glycart Ag uso de um anticorpo b-ly1 humanizado e um ou mais agentes quimioterápicos selecionados do grupo consistindo em ciclofosfamida,vincristina e doxorubicina para a fabricação de um medicamento para o tratamento de um linfoma não hodgkin de células b (nhl)
WO2009134738A1 (en) 2008-04-29 2009-11-05 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
ES2498741T3 (es) 2008-09-10 2014-09-25 F. Hoffmann-La Roche Ag Dispositivo de administración para uso con un fármaco terapéutico
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
JP5524967B2 (ja) 2008-09-19 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規抗体処方物
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010279569A1 (en) 2009-08-04 2012-03-01 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP4029881A1 (en) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
WO2013031266A1 (ja) 2011-08-26 2013-03-07 テルモ株式会社 シリンジ及びシリンジ収納容器

Also Published As

Publication number Publication date
JP6934919B2 (ja) 2021-09-15
SMT201600176B (it) 2016-08-31
EP4218716A1 (en) 2023-08-02
KR101782195B1 (ko) 2017-09-26
MY174009A (en) 2020-03-03
GT201200069A (es) 2014-05-26
EP3064196A1 (en) 2016-09-07
NZ621448A (en) 2015-07-31
AR078161A1 (es) 2011-10-19
US20150086537A1 (en) 2015-03-26
BR112012005017B1 (pt) 2021-09-08
RS54769B1 (sr) 2016-10-31
IL218165A0 (en) 2012-07-31
KR20140006112A (ko) 2014-01-15
ZA201201605B (en) 2019-09-25
TWI515020B (zh) 2016-01-01
ES2574052T3 (es) 2016-06-14
IL249066A0 (en) 2017-01-31
US10377831B2 (en) 2019-08-13
EA031972B1 (ru) 2019-03-29
LT3061445T (lt) 2023-09-25
SMT202300282T1 (it) 2023-11-13
SG179030A1 (en) 2012-04-27
DK3061445T3 (da) 2023-09-11
HRP20160807T1 (hr) 2016-08-26
CL2012000620A1 (es) 2013-09-06
US20190367629A1 (en) 2019-12-05
EA201200475A1 (ru) 2012-10-30
HUE029078T2 (en) 2017-02-28
US20250197520A1 (en) 2025-06-19
KR101782301B1 (ko) 2017-09-26
HUE062860T2 (hu) 2023-12-28
FI3061445T3 (fi) 2023-08-30
JP6364310B2 (ja) 2018-07-25
CY1117941T1 (el) 2017-05-17
PE20121178A1 (es) 2012-09-06
HK1174553A1 (en) 2013-06-14
PE20151425A1 (es) 2015-09-18
TW201429506A (zh) 2014-08-01
CN104399075A (zh) 2015-03-11
EP2475353A2 (en) 2012-07-18
BR112012005017B8 (pt) 2021-09-21
TW201114449A (en) 2011-05-01
PH12016501002A1 (en) 2018-01-29
MX360435B (es) 2018-10-31
US10752696B2 (en) 2020-08-25
KR20170034441A (ko) 2017-03-28
SI2475353T1 (sl) 2016-08-31
MY197773A (en) 2023-07-13
PL3061445T3 (pl) 2023-11-06
TWI515021B (zh) 2016-01-01
PL2475353T3 (pl) 2016-10-31
DOP2012000064A (es) 2012-05-31
CR20120090A (es) 2012-07-12
CN102686216A (zh) 2012-09-19
MA33592B1 (fr) 2012-09-01
JP2015061839A (ja) 2015-04-02
PT3061445T (pt) 2023-08-28
EP2475353B1 (en) 2016-04-13
JP2017200924A (ja) 2017-11-09
EP3061445A1 (en) 2016-08-31
DOP2016000110A (es) 2016-08-15
CA2771571C (en) 2013-11-12
US10280227B2 (en) 2019-05-07
TN2012000101A1 (en) 2013-09-19
IL218165A (en) 2016-12-29
PH12016501002B1 (en) 2018-01-29
US20160137742A1 (en) 2016-05-19
JP2020011962A (ja) 2020-01-23
NZ598653A (en) 2014-03-28
HRP20231019T1 (hr) 2023-12-08
BR112012005017A2 (pt) 2020-10-27
AU2010294186A1 (en) 2012-03-08
IL249066B (en) 2018-02-28
CA2771571A1 (en) 2011-03-17
EP4218715A1 (en) 2023-08-02
US20210054092A1 (en) 2021-02-25
WO2011029892A2 (en) 2011-03-17
AU2010294186B2 (en) 2013-09-19
WO2011029892A3 (en) 2011-09-15
CO6440527A2 (es) 2012-05-15
DK2475353T3 (en) 2016-05-30
US20110076273A1 (en) 2011-03-31
JP2013504540A (ja) 2013-02-07
ES2953478T3 (es) 2023-11-13
ECSP12011722A (es) 2012-04-30
SI3061445T1 (sl) 2023-10-30
EA201792552A1 (ru) 2018-09-28
MX2012002861A (es) 2012-04-20
HK1208176A1 (en) 2016-02-26
MX360432B (es) 2018-10-31
JP5674788B2 (ja) 2015-02-25
KR20120051094A (ko) 2012-05-21
CN102686216B (zh) 2014-11-05
CN104399075B (zh) 2018-11-06
EP3061445B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
SG179030A1 (en) Highly concentrated pharmaceutical formulations comprising anti - cd20 antibody
EP4257150A8 (en) Subcutaneous anti-her2 antibody formulation
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
WO2010100200A3 (en) Lyophilised antibody formulation
TH151334A (th) สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody)